BioNTech’s acquisition of fellow German mRNA company CureVac underscored a trend in biotech: many companies form around new technologies, but not all succeed.
Key Takeaways
- BioNTech’s $1.2bn all-stock acquisition of CureVac was probably a bittersweet exit for CureVac investors at fractional valuations of both companies’ pandemic highs.
BioNTech’s acquisition of CureVac must have been a bittersweet transaction on several levels. At the time...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?